In vitro activities of two new antifungal azoles.
AUTOR(ES)
Hoeprich, P D
RESUMO
The antifungal activities of equimolar quantities of three azole compounds, Bay n 7133 [1-(4-chlorophenoxy)-3,3-dimethyl-2-(1,2,4-triazole-1-yl)methylbutan-2-O1], Bay 1 19139 [1-(4-chlorophenoxy)-1-(1-imidazolyl)-3,3-dimethyl-2-butanol hydrochloride], and ketoconazole, were compared by testing the susceptibility in vitro of 10 clinical isolates each of Candida albicans, Candida parapsilosis, Torulopsis glabrata, Cryptococcus neoformans, Aspergillus fumigatus, Aspergillus niger, Aspergillus flavus, Rhizopus spp., Mucor spp., and Coccidioides immitis. Molecule for molecule, ketoconazole was consistently the most active drug. All three azoles were primarily fungistatic, although they were fungicidal at clinically relevant concentrations against some strains of A. niger.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=185512Documentos Relacionados
- Effect of cyclodextrin on the pharmacology of antifungal oral azoles.
- In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles.
- Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii.
- In Vitro Activities of New Antifungal Agents against Chaetomium spp. and Inoculum Standardization
- In Vitro Activities of New and Conventional Antifungal Agents against Clinical Scedosporium Isolates